copaydosingefficacyresourcesafety

THIS SITE IS INTENDED FOR US AUDIENCES ONLY

You are about to enter the otezlapro.com site, which is intended for
healthcare professionals in the United States.
By selecting an indication, you certify that you are a licensed healthcare professional.

Please see Important Safety Information presented throughout
this site and Full Prescribing Information.

Enlarged image of 2 Otezla® (apremilast) 30mg tablets surrounded by 5 people in various activities
Results the way They Want Them
Otezla® (apremilast) has a proven efficacy and safety profile, oral dosing, and no label-required lab monitoring—making it a treatment experience patients can respond to.*
*Otezla significantly increased PASI-75 response (n = 562) at week 16 (primary endpoint) vs placebo (n = 282) (33% vs 5%; P < 0.0001)

The efficacy and safety of Otezla was evaluated in 2 multicenter, double-blind, placebo-controlled trials of similar design. Patients with moderate to severe plaque psoriasis (N = 1257) were randomized 2:1 to Otezla 30 mg BID or placebo for 16 weeks after a 5-day titration.


See study design
Otezla significantly increased ACR20 response (n = 168) at week 16 (primary endpoint) vs placebo (n = 168) (38% vs 19%; P = 0.0001)

The efficacy and safety of Otezla was evaluated in 3 multicenter, randomized, double-blind, placebo-controlled phase 3 trials in adult patients with active psoriatic arthritis (N = 1493). Patients were randomized 1:1:1 to either Otezla 30 mg twice daily, Otezla 20 mg twice daily, or placebo for 24 weeks, after a 5-day titration period.


See study design

Indications & Important Safety Information

Please click here for Full Prescribing Information.

You are leaving the Otezla® (apremilast) website

Do you wish to leave this site?

Are You a
Healthcare Professional?

Getting Otezla Gets Even Easier

8 out of 10commercially insured lives in the US have preferred access with no biologic step required for Otezla® (apremilast)1

Click here for a complete list of plans
Reference: 1. Data on file, Celgene Corporation.
01/18 USII-APR180063